Celgene Co. (CELG) Shares Bought by Commonwealth Bank of Australia

Commonwealth Bank of Australia grew its holdings in Celgene Co. (NASDAQ:CELG) by 40.8% during the 1st quarter, HoldingsChannel reports. The fund owned 115,793 shares of the biopharmaceutical company’s stock after acquiring an additional 33,561 shares during the period. Commonwealth Bank of Australia’s holdings in Celgene were worth $10,915,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Investors Research Corp purchased a new stake in shares of Celgene in the first quarter worth about $28,000. Mizuho Securities Co. Ltd. bought a new stake in Celgene during the first quarter worth approximately $31,000. Creative Financial Designs Inc. ADV increased its stake in Celgene by 1,968.8% during the first quarter. Creative Financial Designs Inc. ADV now owns 331 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 315 shares during the last quarter. Bruderman Asset Management LLC bought a new stake in Celgene during the fourth quarter worth approximately $25,000. Finally, Murphy Pohlad Asset Management LLC bought a new stake in Celgene during the fourth quarter worth approximately $25,000. Institutional investors and hedge funds own 75.09% of the company’s stock.

Several equities research analysts have weighed in on CELG shares. BidaskClub raised Celgene from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. William Blair reissued a “buy” rating on shares of Celgene in a research note on Thursday, February 28th. Cantor Fitzgerald cut Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price objective on the stock. in a research note on Friday, April 5th. Cowen started coverage on Celgene in a research note on Tuesday, February 26th. They set a “market perform” rating and a $102.00 price objective on the stock. Finally, Sanford C. Bernstein cut Celgene from an “outperform” rating to a “market perform” rating in a research note on Monday, April 1st. Eighteen equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $95.56.

CELG opened at $95.34 on Wednesday. The company has a market cap of $66.72 billion, a PE ratio of 12.53, a price-to-earnings-growth ratio of 0.43 and a beta of 1.57. Celgene Co. has a one year low of $58.59 and a one year high of $97.07. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 2.42.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.10. The firm had revenue of $4.03 billion for the quarter, compared to analysts’ expectations of $4.01 billion. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The company’s quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 earnings per share. As a group, equities research analysts predict that Celgene Co. will post 9.85 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Celgene Co. (CELG) Shares Bought by Commonwealth Bank of Australia” was originally reported by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.wkrb13.com/2019/06/05/celgene-co-celg-shares-bought-by-commonwealth-bank-of-australia.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Article: What is a Buy-Side Analyst?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.